talquetamab will increase the degree or effect of ergotamine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of. Talquetamab results in cytokine release syndrome (CRS) which will suppress exercise of CYP enzymes, causing greater publicity of CYP substrates.Headache, intermittent claudication, muscle pains, numbness,